The G7 countries met (virtually) on Friday, February 19, to share variants of “no one is safe until everyone is safe” and discuss the importance of global equity of Covid-19 vaccines and the need for international cooperation. (Sound familiar? That’s because we heard the same things from the G20 in November.)
This past week, we saw the first direct vaccine purchases made for low-income countries with the
African Union’s purchase of 270 million doses of Covid-19 vaccines from Pfizer-BioNTech, OxfordAstraZeneca, and Johnson & Johnson (J&J). Though it is a relatively modest purchase, it represents a significant shift in the global power dynamics of the Covid-19 response.
The Serum Institute of India (SII), one of the world’s largest vaccine manufacturers, has publicly
committed that half of the Covid-19 vaccines they produce will stay in India to serve the domestic
market, while the remainder will be shipped out to other countries. This week, we have changed the way that India’s reserved doses of vaccine are represented in our data.